Triple‐negative breast cancer (TNBC) represents a subgroup of about 15–20% of breast tumors that lacks expression of three main biomarkers: estrogen receptor (ER), progesterone receptor, and epidermal growth factor receptor 2 (HER2) amplification (Bianchini et al., 2016). Here, ESR1 is linked to breast neoplasm.